• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Cutting Edge CRISPR Therapeutics Has Cut a Path Higher

Let's review the charts and indicators.
By BRUCE KAMICH
Dec 22, 2020 | 03:00 PM EST
Stocks quotes in this article: CRSP

CRISPR Therapeutics (CRSP) is soaring to new highs today. I last looked at CRSP back on October 5 and wrote that, "I am not yet convinced that CRSP can rally strongly BUT a close above $89 tells me that traders could go long risking a close below $80. Take profits around $102 if available." 

 
Prices rallied in October to around $110 and then retreated into early November. We could say that was a "good call" except after the pullback prices have nearly doubled in about two months. 
 
Yes, you read that right. What do the charts and indicators suggest now? 
 
In this daily Japanese candlestick chart of CRSP, below, we can see that prices consolidated around the $150 area before its latest spike higher. CRSP is trading above the rising 50-day moving average line and should be considered extended above the rising 200-day moving average line which intersects down around $82 or so. With prices of CRSP more than double the 200-day line it meets my criteria for being extended or overbought.
 
The On-Balance-Volume (OBV) line was steady from July to late November and has since turned higher to confirm the price gains.
 
The Moving Average Convergence Divergence (MACD) oscillator has been very strong and bullish since early November. 
 
 
In this weekly Japanese candlestick chart of CRSP, below, we can see that prices made a base pattern around the $40 area and multiples of $40 have turned out to be price targets - we just passed the four-fold target of $160. Prices are above the rising 40-week moving average line.
 
The weekly OBV line is strong and tells us that buyers of CRSP have been more aggressive for a log time. The MACD oscillator is bullish. 
 
 
In this Point and Figure chart of CRSP, below, we twisted and turned and tweaked the parameters to come up with a new and higher price target. We used weekly price data with a five-box reversal instead of the standard three-box filter. A potential target of $230 is being shown. A daily Point and Figure chart only had a target of $140 which was left in the dust.
 
 
 
Bottom line strategy: If you are still long CRSP then you are way smarter than me. Longs should risk to $145. The round number of $200 and then the Point and Figure target of $230 are the price objectives for now.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology

More from Investing

The Market's 'Generals' Are Now in the Crosshairs

James "Rev Shark" DePorre
May 18, 2022 4:42 PM EDT

We've reached the next phase of the bear market, as big names get hit.

These Three Small-Cap Stocks Boast Big Dividends

Bob Ciura
May 18, 2022 3:00 PM EDT

Look beyond the mega-cap names for income investing to the more inclusive -- and often smaller -- Dividend Champions.

Can Nvidia Make a Rebound Rally Ahead of Earnings?

Bruce Kamich
May 18, 2022 2:32 PM EDT

Here's what I'd look for NVDA to do in the days ahead.

After Cisco Reports, Will There Be a Tradable Rally?

Bruce Kamich
May 18, 2022 12:04 PM EDT

Let's see how the charts look before earnings Wednesday night.

ServiceNow Picks Up a New Bull on Their Shares

Bruce Kamich
May 18, 2022 11:20 AM EDT

Here's what aggressive traders could do now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login